FDA reviewers question proposed study design for Salix's Xifaxan in IBS
This article was originally published in Scrip
Shares of Salix Pharmaceuticals tumbled as low as 11.3% on 14 November, or $4.24, after US drug reviewers questioned whether a new trial design for the firm's antibiotic Xifaxan (rifaximin) would gauge whether the drug is effective and safe in treating patients with irritable bowel syndrome with diarrhea (IBS-D).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.